BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37725576)

  • 1. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
    Paolino J; Dimitrov B; Apsel Winger B; Sandoval-Perez A; Rangarajan AV; Ocasio-Martinez N; Tsai HK; Li Y; Robichaud AL; Khalid D; Hatton C; Gillani R; Polonen P; Dilig A; Gotti G; Kavanagh J; Adhav AA; Gow S; Tsai J; Li Y; Ebert BL; Van Allen EM; Bledsoe J; Kim AS; Tasian SK; Cooper SL; Cooper TM; Hijiya N; Sulis ML; Shukla NN; Magee JA; Mullighan CG; Burke MJ; Luskin MR; Mar BG; Jacobson MP; Harris MH; Stegmaier K; Place AE; Pikman Y
    Clin Cancer Res; 2023 Nov; 29(22):4613-4626. PubMed ID: 37725576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
    Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
    Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
    Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
    Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
    Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
    Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
    Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
    Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.
    Capovilla M; Cayuela JM; Bilhou-Nabera C; Gardin C; Letestu R; Baran-Marzak F; Fenaux P; Martin A
    Eur J Haematol; 2008 Jan; 80(1):81-6. PubMed ID: 18028420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDGFRA rearrangement leading to hyper-eosinophilia, T-lymphoblastic lymphoma, myeloproliferative neoplasm and precursor B-cell acute lymphoblastic leukemia.
    Huang Q; Snyder DS; Chu P; Gaal KK; Chang KL; Weiss LM
    Leukemia; 2011 Feb; 25(2):371-5. PubMed ID: 21304535
    [No Abstract]   [Full Text] [Related]  

  • 9. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-PDGFRA fusion in a T lymphoblastic leukemia/lymphoma.
    Yigit N; Wu WW; Subramaniyam S; Mathew S; Geyer JT
    Cancer Genet; 2015; 208(7-8):404-7. PubMed ID: 26095243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
    Huang YH; Wan CL; Dai HP; Xue SL
    Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2010; 72(1-2):55-70. PubMed ID: 20726440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
    DuVall AS; Wesevich A; Larson RA
    Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P
    Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
    De Coninck S; De Smedt R; Lintermans B; Reunes L; Kosasih HJ; Reekmans A; Brown LM; Van Roy N; Palhais B; Roels J; Van der Linden M; Van Dorpe J; Ntziachristos P; Van Delft FW; Mansour MR; Pieters T; Lammens T; De Moerloose B; De Bock CE; Goossens S; Van Vlierberghe P
    Haematologica; 2024 May; 109(5):1373-1384. PubMed ID: 37941480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
    von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
    BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma.
    Akiely R; Almasri F; Almasri N; Abu-Ghosh A
    Front Pediatr; 2022; 10():1059527. PubMed ID: 36589160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma.
    Salmerón-Villalobos J; Ramis-Zaldivar JE; Balagué O; Verdú-Amorós J; Celis V; Sábado C; Garrido M; Mato S; Uriz J; Ortega MJ; Gutierrez-Camino A; Sinnett D; Illarregi U; Carron M; Regueiro A; Galera A; Gonzalez-Farré B; Campo E; Garcia N; Colomer D; Astigarraga I; Andrés M; Llavador M; Martin-Guerrero I; Salaverria I
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29926. PubMed ID: 36000950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
    De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
    Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.